1476848-27-7 Usage
Uses
Used in Organic Synthesis:
1-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoethanone is used as a building block in organic synthesis for the creation of more complex molecules. Its unique structure and functional groups, including the benzyloxy and methoxy substitutions on the benzofuran ring and the bromine atom attached to the ketone, make it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoethanone is used as a starting material or intermediate in the development of new drugs. Its structural features may contribute to the design of novel therapeutic agents with specific biological activities, such as anti-inflammatory, anti-cancer, or anti-microbial properties. The bromine atom in particular may be exploited for further functionalization or as a handle for drug-targeting strategies.
Caution:
Due to the presence of a bromine substituent, which can be potentially hazardous, care should be taken when handling 1-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoethanone. Appropriate safety measures, including the use of personal protective equipment and proper disposal methods, should be followed to minimize risks associated with 1-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoethanone.
Check Digit Verification of cas no
The CAS Registry Mumber 1476848-27-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,7,6,8,4 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1476848-27:
(9*1)+(8*4)+(7*7)+(6*6)+(5*8)+(4*4)+(3*8)+(2*2)+(1*7)=217
217 % 10 = 7
So 1476848-27-7 is a valid CAS Registry Number.
1476848-27-7Relevant academic research and scientific papers
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy
Miller, Michael M.,Banville, Jacques,Friends, Todd J.,Gagnon, Mark,Hangeland, Jon J.,Lavallée, Jean-Fran?ois,Martel, Alain,O'Grady, Harold,Rémillard, Roger,Ruediger, Edward,Tremblay, Fran?ois,Posy, Shana L.,Allegretto, Nick J.,Guarino, Victor R.,Harden, David G.,Harper, Timothy W.,Hartl, Karen,Josephs, Jonathan,Malmstrom, Sarah,Watson, Carol,Yang, Yanou,Zhang, Ge,Wong, Pancras,Yang, Jing,Bouvier, Michel,Seiffert, Dietmar A.,Wexler, Ruth R.,Lawrence, R. Michael,Priestley, E. Scott,Marinier, Anne
, p. 7400 - 7416 (2019/08/26)
In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure-activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.
PAR4 AGONIST PEPTIDES
-
Page/Page column, (2013/11/06)
The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.
